|
- A new way to treat disease is on the horizon. - REGENXBIO
We believe that what we do matters – to patients, to their families and to their communities We set a high bar for having a culture focused on patients, driven by results, and one that fosters collaboration
- Catalytic converters, the future of metal recovery | RegenX
Regenx is leading a revolution in the recovery of precious metals from end-of-life diesel catalytic converters A sustainable solution that minimizes waste, conserves resources, and reduces environmental impact
- RegenX Science Home - RegenXScience
At RegenX Science, we have developed a proprietary regenerative biomaterial inspired by one of nature’s most remarkable healing organisms This technology harnesses cutting-edge molecular biology and regenerative medicine techniques to create products that transform patient care
- Regenxbio Inc
Explore Regenxbio Inc's dedication to gene therapy innovation, focusing on retinal, metabolic, and neurodegenerative diseases for transformative patient care
- Regenx Tech Expands Processing Capacity to 4,000 lbs, Awaits Final . . .
Regenx Tech is a cleantech, urban mining company that recycles end-of-life diesel catalytic converters using its innovative and environmentally friendly proprietary technology for the recovery of precious metals, such as platinum and palladium Learn more at www regenx tech For further information contact: REGENX TECH CORP Investors
- Regenxbios RGX-121 Could Become The New Standard Of Care In Hunter . . .
Regenxbio (NASDAQ:RGNX) is a clinical-stage biopharmaceutical company focusing on gene therapies Founded in 2008, the core technology of the company is the delivery of rescue genes using AAV
- Who We Are - REGENXBIO
We are currently developing gene therapy product candidates for the treatment of retinal, metabolic, and neurodegenerative diseases Our product candidates all utilize AAV viral vectors from our proprietary gene delivery platform, which we call our NAV® Technology Platform
- REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I II AFFINITY . . .
AFFINITY DUCHENNE Pivotal Trial REGENXBIO is enrolling participants in the pivotal portion of the Phase I II III AFFINITY DUCHENNE trial of RGX-202 The trial is expected to enroll approximately 30 patients aged 1+ in the U S and Canada by 2025, with more than half already enrolled to support the pivotal dataset
|
|
|